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Introduction 
Immune checkpoint inhibitor therapies are used in 
the treatment of numerous malignancies. Although 
inducing immune activation with strong anti-tumor 
effects, they can lead to toxicities, known as immune-
related adverse events (irAEs), which may affect any 
organ system [1]. Bullous dermatoses, most 
frequently bullous pemphigoid (BP), may cause 
interruption and discontinuation of immunotherapy 
owing to potential extensive skin involvement and 
complications [2]. Because toxicities of anti-PD-
1/anti-PD-L1 agents are frequently grouped 
together, differences in irAE risk between anti-PD-1 
and anti-PD-L1 agents have not been examined. 
Herein, we present a patient with anti-PD-L1-
induced BP and review reported cases of bullous 
dermatoses secondary specifically to anti-PD-L1 
agents. 
 
Case Synopsis 
An 87-year-old man with urothelial cell carcinoma 
initiated immunotherapy treatment with anti-PD-L1 
agent atezolizumab, after no response to carboplatin 
and gemcitabine. He experienced mild, diffuse 
pruritus until, at 18 months, he developed “chicken 
pox-like blisters” on the left forearm. The patient 
continued immunotherapy for three more months at 
which time atezolizumab was held owing to 
progression of the bullous eruption; he was referred 
to the dermatology department. 
Abstract 
Immune checkpoint inhibitors are used to treat 
numerous malignancies but may be associated with 
severe adverse events. Bullous dermatoses, chiefly 
bullous pemphigoid (BP), are potentially progressive 
adverse events that cause blistering skin lesions and 
may involve a significant body surface area. Herein, 
we report an 87-year-old man with urothelial cell 
carcinoma undergoing atezolizumab treatment who 
presented with an acute-onset blistering eruption. 
Biopsy revealed a subepidermal bulla, direct 
immunofluorescence revealed linear IgG and C3 
deposits at the dermal-epidermal junction, and 
serum studies revealed elevated levels of antibodies 
to BP180 and BP230. Anti-PD-L1-induced BP was 
diagnosed, immunotherapy was withheld, and he 
was treated with oral doxycycline with niacinamide 
and clobetasol ointment. He restarted atezolizumab 
and has successfully received four cycles (every 3 
weeks) while continuing this BP treatment regimen. 
A literature review revealed eight other cases of anti-
PD-L1-induced bullous disorders. The incidence of 
bullous dermatoses with anti-PD-1/anti-PD-L1 
agents combined is 1%, whereas the reported 
incidence for anti-PD-L1 agents alone ranges from 
1.3-5%, raising concerns for a higher overall risk. In 
addition to our case, only one other case reported 
successful resumption of immunotherapy. Early 
control and management of immunotherapy-
induced BP may reduce complications and prevent 
treatment discontinuation. 
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Physical examination demonstrated numerous 
intact, tense bullae, some with adjacent erosions and 
crusting, localized on the posterior neck, left 
posterior shoulder, abdomen, arms, and legs (Figure 
1). The largest bulla was approximately 3cm with 
several smaller 5-6mm vesicles. The oral and ocular 
mucosae were unaffected. 
Lesional edge punch biopsy revealed a sub-
epidermal pauci-cellular blister on hematoxylin and 
eosin (H&E) staining. Perilesional punch biopsy for 
direct immunofluorescence (DIF) showed linear IgG 
and C3 deposits at the dermal-epidermal junction 
(Figure 2). Anti-BP230 IgG levels were 13U/mL 
(reference range <9U/mL), and anti-BP180 IgG levels 
were 22U/mL (reference range <14U/mL). As a result, 
anti-PD-L1-induced BP was diagnosed. 
The patient was started on 100mg oral doxycycline 
twice daily, 500mg oral niacinamide twice daily, and 
topical clobetasol 0.05% ointment twice daily to 
affected areas. Three months after BP treatment 
initiation, the blisters completely resolved. 
Atezolizumab treatment was held for a total of nine 
weeks (three cycles), at which point it was restarted 
with close clinical monitoring. He has since received 
four additional immunotherapy cycles while 
continuing the doxycycline, niacinamide, and 
clobetasol ointment with only mild intermittent 
pruritus. He continues to be monitored and remains 
on atezolizumab therapy. 
 
Case Discussion 
There is limited evidence focusing on the incidence 
and characterization of anti-PD-L1-induced bullous 
dermatoses. Anti-PD-L1 immunotherapy targets the 
PD-L1, expressed in non-T lymphocytes (e.g., 
antigen-presenting cells), thus relieving the 
inhibition on T cell-mediated immune response [3]. 
However, the autoantibody-mediated reaction in 
bullous dermatoses likely signifies B lymphocyte 
involvement as well [4]. This reaction may represent 
enhancement of a pre-existing autoantibody 
response or an entirely new process directly caused 
by immunotherapy treatment [4]. 
There have been nine reported cases of patients who 
developed bullous dermatoses during anti-PD-L1 
therapy. These nine cases showed an average patient 
age of 70.5 years with an average time to dermatosis 
diagnosis of 9.4 months (Table 1). The prolonged 
latency is a unique feature of immunotherapy-
induced bullous dermatoses because most 
dermatologic irAEs occur early in treatment, often 
 
Figure 2. Histopathological image demonstrating a sub-
epidermal pauci-cellular bulla with eosinophils. H&E, 100×; scale 
bar=100m. 
 
Figure 1. Clinical photograph demonstrating lower extremity 
with an erythematous patch and a tense bulla. 
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after the first cycle [1]. The reported malignancies 
and specific anti-PD-L1 agents were varied, reflecting 
the primary cancers being treated with anti-PD-L1 
agents. Reported incidence rates of anti-PD-L1-
induced bullous dermatoses (1.35%, 5%), [2, 5], are 
higher than the reported 1% for PD-1/PD-L1 
combined [2]. In the setting of a bullous dermatosis 
during anti-PD-L1 therapy, switching to an anti-PD-1 
agent or another class of checkpoint inhibitor may 
be warranted. 
For bullous dermatoses, helpful diagnostic tools 
include lesional biopsy for H&E staining, perilesional 
biopsy for DIF, and serologic testing for anti-BP180 
and anti-BP230 antibodies. All studies found in our 
literature review that performed a skin biopsy found 
classic BP on histopathology and 
immunofluorescence analysis. In addition, in the 
three cases that tested for autoantibodies, positive 
results were reported. Skin biopsy and serum studies 
may aid in distinguishing between bullous 
dermatoses and other dermatologic reactions early 
in presentation. Treatment of immunotherapy-
induced bullous dermatoses is similar to the 
treatment of classic BP. Corticoteroids, doxycycline, 
nicotinamide, methotrexate, and rituximab have 
been utilized successfully [2, 7, 8]. In all but one of the 
reviewed studies that reported treatment, oral 
prednisone was used to achieve disease control. 
Even with discontinuation of anti-PD-L1 
immunotherapy, aggressive management to 
prevent extensive disease with high morbidity is 
likely necessary. 
None of the nine patients reported a history of 
bullous dermatoses. In our patient, the first 18 
months of pruritus while on anti-PD-L1 therapy may  
have signified subclinical BP or the more common 
clinical scenario of immunotherapy-induced 
pruritus. In two previously reported cases, when anti-
PD-L1 immunotherapy was resumed, BP recurred 
necessitating permanent discontinuation of 
immunotherapy [5]. In one case, immunotherapy 
was not held and the patient was able to continue 
treatment without BP flares [6]. Overall, two of 9 
patients remain on anti-PD-L1 immunotherapy 
whereas the remaining 7 had to discontinue 
treatment. Regarding response to immunotherapy, 5 
of 6 patients with reported treatment response in the 
review had a partial response to immunotherapy and 
the final case reported stable disease. The marked 
response to immunotherapy is contrasted by the 
frequent need for treatment discontinuation. Early 
and effective control of these bullous reactions may 
prevent the need for treatment discontinuation and 
allow for continued response to anti-PD-L1 agents. 
 
Conclusion 
To the best of our knowledge, this is only the second 
reported case of successfully restarting anti-PD-L1 
therapy in a patient who developed 
immunotherapy-induced BP. Dermatologic referral 
should occur at the onset of any skin reaction 
believed to be secondary to immunotherapy. This 
case highlights the importance of prompt and 
aggressive management of immunotherapy-
induced bullous pemphigoid, potentially allowing 
patients to remain on these life-sustaining therapies. 
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Table 1. Reported cases of anti-PD-L1-induced bullous dermatoses.  
 
Article Age Sex Malignancy 
Anti-PD-L1 
Agent  
Histology/ 
Immuno-
fluorescence 
Serum 
Studies
Time to 
development 
(months) 
Effect on 
immunotherapy Treatment 
Response to 
treatment 
Response to 
immunotherapy 
(complete, 
partial, none) 
Kaunitz, 
G., et al. 
[9] 
65 M NSCLC* Not-specified n/a n/a 9 
Delayed, 
rechallenged and 
discontinued with 
BP flare 
Clobetasol spray, 
prednisone n/a n/a 
Naidoo, 
J., et al. 
[10] 
78 F 
Metastatic 
melanoma Durvalumab n/a n/a 12 Discontinued 
Clobetasol solution 
0.05% 
Moderate 
response, still 
recurred 
occasionally 1 
year later 
Partial response 
Russo, I., 
et al. [11] 59 M NSCLC* Atezolizumab n/a n/a 15 Discontinued 
Prednisone 
50mg/d, 
doxycycline  
Complete 
response n/a 
Shen, J., 
et al. [6] 67 F 
Metastatic 
adreno-
cortical 
carcinoma 
Avelumab 
First biopsy: 
epidermal 
spongiosis and 
intraepidermal 
neutrophilic and 
eosinophilic 
pustules, 
consistent with 
a dermal 
hypersensitivity 
reaction; second 
biopsy: 
eosinophilic 
spongiosis with 
focal 
subepidermal 
clefting, DIF 
with 2+ focal C3 
staining 
(nonspecific) 
n/a n/a No treatment interruption 
Clotrimazole cream,
hydrocortisone, 
TAC ointment, 
prednisone 
10 mg/d, 
dexamethasone 
n/a Partial response 
Siegel, J., 
et al. [2] 
77 F Urothelial 
cell 
Atezolizumab 
HE: 
Subepidermal 
bulla  
DIF: IgG and C3 
BP180 
level: 47
5 Discontinued 
Topical CS, 
prednisone, 
omalizumab, 
methotrexate
Complete 
response 
with 
Partial response 
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at DEJ 
IIF: IgG and C3 at 
DEJ 
persistent 
pruritus 
Siegel, J., 
et al. [2] 66 F AML Durvalumab 
HE: 
Subepidermal  
bulla, 
neutrophils  
DIF: IgG, IgA  
and C3 at DEJ  
IIF: Intercellular 
IgG (1:80) and  
IgA (1:10) 
BP180 
level: 18 0.5 Discontinued 
Topical CS, 
prednisone, 
dapsone 
Complete 
response Stable disease 
Strauss, 
J., et al. 
[5] 
n/a n/a 
Mismatch 
repair 
deficient 
pancreatic 
cancer 
m7824 (anti-PD-
L1) n/a n/a 6 
Delayed, 
rechallenged and 
discontinued with 
BP flare 
n/a n/a 
Partial response, 
progression upon 
discontinuation 
Fontecill
a, et al. 
[12] 
65 F NSCLC 
Durvalumab+ 
Tremelimumab 
HE: 
Subepidermal 
blister, 
epidermal 
necrosis, 
perivascular 
lymphocytic 
infiltrate of 
lymphocytes 
and eosinophils.
DIF: intermittent 
linear IgG and 
C3 at DEJ
n/a 10 Held (indefinitely) Oral prednisone 
Complete 
response  n/a 
Current 
report 87 M 
Urothelial 
cell Atezolizumab 
HE: 
Subepidermal 
paucicellular 
blister 
DIF: IgG and C3 
at DEJ
BP230 
level: 13
BP180 
level: 22
18 Held and recontinued  
Doxycycline, 
niacinamide, 
clobetasol 
ointment 
Complete 
response Partial response 
 
Abbreviations: NSCLC: non-small cell lung cancer, n/a: not available, AML: acute myeloid leukemia, CS: corticosteroids, DEJ: dermal-epidermal junction. 
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